Stem Cell Clinic

Glass House Brands Named to 2025 OTCQX Best 50 for the Second Year in a Row

By Global News Feed

LONG BEACH, Calif. and TORONTO, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest-growing, vertically-integrated cannabis companies in the U.S., is pleased to announce it has been named to the 2025 OTCQX® Best 50, a ranking of top performing companies traded on the OTCQX Best Market last year.

Read the rest here:
Glass House Brands Named to 2025 OTCQX Best 50 for the Second Year in a Row

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance

By Global News Feed

SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2024, and provided full year 2025 financial guidance.

Continue reading here:
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance

Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

By Global News Feed

BASKING RIDGE, N.J., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present a corporate overview at the upcoming Sequire Investor Summit being held January 21-23, 2025 in San Juan, Puerto Rico.

Here is the original post:
Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

Metagenomi Announces New Appointment to its Board of Directors

By Global News Feed

EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Eric Bjerkholt, MBA, CFO of Mirum Pharmaceuticals, Inc., will join Metagenomi’s Board of Directors, serving on Metagenomi’s Audit and Compensation committees, effective January 27, 2025.

View post:
Metagenomi Announces New Appointment to its Board of Directors

Tersa Earth Innovations and Precient Technologies Forge Strategic Partnership to Revolutionize Mining Industry

By Global News Feed

BURNABY, British Columbia, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Tersa Earth Innovations Inc., a pioneering Canadian cleantech startup led by CEO and co-founder Barinder Rasode, is excited to announce the signing of a Memorandum of Understanding (MOU) with Precient Technologies.

Excerpt from:
Tersa Earth Innovations and Precient Technologies Forge Strategic Partnership to Revolutionize Mining Industry

Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn’s & Colitis Foundation Congress

By Global News Feed

LOS ANGELES, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the Crohn’s & Colitis Congress (CCC) Annual Meeting. Drs. Peter M. Clark, of the University of California Los Angeles, and Kenneth A. Schultz, of Trethera, will present preclinical research highlighting the use of Trethera’s deoxycytidine kinase (dCK) inhibitor, TRE-515, that suggests a functional role for nucleoside salvage and dCK in inflammatory bowel disease (IBD) mouse models.

Continue reading here:
Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn’s & Colitis Foundation Congress

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome…

By Global News Feed

JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances for GOHIBIC® (vilobelimab) for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of standard of care and receiving invasive mechanical ventilation (IMV) with or without extracorporeal membrane oxygenation (ECMO). GOHIBIC is the first and only treatment approved in the European Union for the treatment of SARS-CoV-2-induced ARDS.

See the rest here:
InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome...

←